Management of Blood Loss in Hip Arthroplasty: Korean Hip Society Current Consensus.
- Author:
Joo Hyoun SONG
1
;
Jang Won PARK
;
Young Kyun LEE
;
In Sung KIM
;
Jae Hwi NHO
;
Kyung Jae LEE
;
Kwan Kyu PARK
;
Yeesuk KIM
;
Jai Hyung PARK
;
Seung Beom HAN
Author Information
- Publication Type:Review
- Keywords: Transfusion; Blood management; Hip arthroplasty
- MeSH: Anemia; Arthroplasty*; Blood Transfusion; Consensus*; Erythropoiesis; Fibrinolysis; Hemorrhage; Hip*; Hospitalization; Humans; Incidence; Iron; Lysine; Tranexamic Acid
- From:Hip & Pelvis 2017;29(2):81-90
- CountryRepublic of Korea
- Language:English
- Abstract: The volume of hip arthroplasty is stiffly increasing because of excellent clinical outcomes, however it has not been shown to decrease the incidence of transfusions due to bleeding related to this surgery. This is an important consideration since there are concerns about the side effects and social costs of transfusions. First, anemia should be assessed at least 30 days before elective hip arthroplasty, and if the subject is diagnosed as having anemia, an additional examination of the cause of the anemia should be carried and steps taken to address the anemia. Available iron treatments for anemia take 7 to 10 days to facilitate erythropoiesis, and preoperative iron supplementation, either oral or intravenous, is recommended. When using oral supplements for iron storage, administer elemental iron 100 mg daily for 2 to 6 weeks before surgery, and calculate the dose using intravenous supplement. Tranexamic acid (TXA) is a synthetic derivative of the lysine component, which reduces blood loss by inhibiting fibrinolysis and clot degradation. TXA is known to be an effective agent for reducing postoperative bleeding and reducing the need for transfusions in primary and revision total hip arthroplasties. Patient blood management has improved the clinical outcome after hip arthroplasty through the introduction and research of various agents, thereby reducing the need for allogeneic blood transfusions and reducing the risk of transfusion-related infections and the duration of hospitalizations.
